Bulgarian government facing renewed pressure to fund biomarker testing
While nearly 30,000 Bulgarians need biomarker diagnostics annually, the state only covers the costs of one biomarker for breast cancer.
Diagnostics
Turning aspirations into action for rare disease patients
Inspired by the rare disease community’s passionate drive to advance policies that provide equitable access to care, UCB spearheaded Aspire4Rare: a global initiative supporting the development of rare disease policies.
AI, new strategies could fast-track cerebral palsy detection, says award-winning researcher [Advocacy Lab Content]
Innovative solutions are driving change in the early diagnosis and intervention of cerebral palsy. Integrating AI into diagnostics and advancing research into neuroplasticity is finally engaging policymakers.
The post AI, new strategies could fast-trac…
Why Europe’s health policies must prioritize chronic kidney disease
Undetected Chronic Kidney Disease affects millions in Europe, but it could be preventable, manageable and tackled with the right policies.
It’s time for Europe to harness the power of medical technology
Using the incredible power of medical technology, Europe can positively transform lives and its healthcare systems
Mission Possible: Working together to reshape the future of cancer care
Q&A with Greg Rossi, Senior VP, Head of Oncology Europe and Canada at AstraZeneca.
Show me the money, Gastein says
SNEAK PEEK — Gastein day 1 kicks off with a plea to ramp up investment in health — and ways to do it. — Can tech help to close the gender health gap? Some think so, but only if its funded and reaches all in need. — Is COP29 the breakthrough year for health and […]
Who’s the real health commissioner?
SNEAK PEEK — EU health policy is now split across multiple departments, and MEPs aren’t happy. — Sort your own house out first: MEPs question Hungarian health secretary over presidency plans and country’s health commissioner role. — Spend less on defense and more on health, WHO chief Tedros told world leaders at the United Nations […]
Tech policy: 20 people to meet at Labour conference
We break down the 20 figures inside and outside government shaping Labour’s tech policy.
Can global leaders agree on a tough AMR plan?
Some experts lament the lack of bolder commitments in farming.
These are the most deadly pathogens — so why aren’t drug companies targeting them?
Despite calls to step up efforts, investment in antimicrobial resistance is still insufficient.
EU’s ability to challenge ‘killer acquisitions’ dealt a blow by Europe’s highest court
Illumina, a global leader in DNA sequencing technologies, has won a battle against the EU over its decision to block the merger between it and Grail, a company specialising in early cancer detection through genetic diagnostics.
EU court rips up Commission’s killer acquisition tool
Judges tell merger regulators to stop scooping up anti-competitive deals outside revenue thresholds.
Bulgaria under pressure to provide free biomarker tests for cancer patients [Advocacy Lab Content]
Patient organizations in Bulgaria are launching a public campaign to force the National Health Insurance Fund (NHIF) to provide free biomarker diagnostics to people with oncological diseases.